Plasma Fractionation Market Global Expansion, Competitive Outlook, and Forecast Opportunities 2032
- sachi toshniwal
- 1 day ago
- 4 min read
The plasma fractionation market involves the collection and separation of human plasma into its key therapeutic components—such as immunoglobulins, clotting factors, albumin, and other plasma-derived proteins—used to treat conditions like immune deficiencies, hemophilia, liver disorders, and certain neurological diseases. Market growth is fueled by the rising prevalence of rare and chronic diseases, increasing use of immunoglobulins for autoimmune and inflammatory disorders, and growing demand for albumin in critical care and surgical applications. Advancements in fractionation technology, improved plasma collection methods, and expanding healthcare access in emerging economies also support market expansion. North America and Europe currently dominate due to well-established plasma collection networks and strong regulatory oversight, while Asia-Pacific is experiencing rapid growth driven by large patient populations and increasing government support for plasma-derived therapies. Key challenges include the high cost and complexity of plasma collection and processing, stringent regulatory requirements, and the ongoing need to ensure a safe, reliable plasma supply
The global plasma fractionation market size was valued at USD 37.31 billion in 2024 and is projected to grow from USD 40.27 billion in 2025 to USD 72.45 billion by 2032, exhibiting a CAGR of 8.75% during the forecast period. North America dominated the plasma fractionation market with a 56.18% share in 2024, supported by advanced healthcare infrastructure, high demand for immunoglobulins and coagulation factors, and strong presence of leading biopharmaceutical companies in the region.
Top Companies in the Market
CSL Behring (CSL) (U.S.)
Grifols, S.A (Spain)
Takeda Pharmaceutical Company Limited (Japan)
Kedrion S.p.A (Italy)
Octapharma (Switzerland)
ADMA Biologics, Inc. (U.S.)
Sartorius AG (Germany)
LFB (France)
Key Industry Development
In July 2024, Kedrion S.p.A. disclosed a major step forward by establishing the framework for a long-term agreement with Biotest AG to fully commercialize and distribute the immunoglobulin therapy Yimmugo in the U.S. market. This alliance reflects the growing strategic emphasis on immunoglobulin therapies and underscores how collaborations are shaping the competitive landscape.
Market Drivers & Restraints
Drivers
Growing burden of chronic and rare diseases: Conditions such as autoimmune disorders, immunodeficiency diseases, and bleeding disorders drive demand for plasma-derived proteins.
Technological advancements & regulatory approvals: Better fractionation techniques, improved pathogen safety measures, and regulatory clearances help launch new therapies.
Strategic investment in plasma collection infrastructure: Players are expanding plasma network footprints to secure feedstock supply.
Rising use of immunoglobulins: Immunoglobulin therapies are becoming front-line options for many immune and neurological conditions, boosting the immunoglobulin segment.
Restraints / Challenges
Limited plasma supply and long processing cycles: The time-intensive nature of plasma collection and fractionation, along with donor limitations, constrains throughput.
High capital intensity & regulatory burden: Setting up fractionation plants demands substantial investment, strict biosafety and regulatory compliance.
Reimbursement and affordability issues: In emerging regions, limited reimbursement and high costs may slow adoption of premium plasma-derived therapies.
Dependence on collaboration & supply agreements: Many players rely on partnerships (as in the Kedrion–Biotest example) — disruptions or disagreements could impact supply chains.
Market Competitive Landscape
The plasma fractionation market is fairly consolidated. Companies such as CSL, Grifols, Octapharma, Takeda, Kedrion, LFB, ADMA Biologics, and Sartorius lead, controlling a large portion of global share. These players continuously invest in innovation, strategic partnerships, capacity expansion, and regulatory filings to defend and expand their positions.
For instance, CSL opened a new plasma manufacturing facility in Victoria, Australia with capacity to process up to 9.2 million plasma equivalent liters per year, enhancing its ability to meet global demand. Moreover, Sartorius AG partnered with Cell & Gene Therapy Catapult to explore albumin-based solutions for advanced therapy manufacturing.
Market Segments
By Product
The market is segmented into immunoglobulins, coagulation factor concentrates, albumin, protease inhibitors, and others. Among these, the immunoglobulin segment commands the largest share, propelled by growing use in immunodeficiency, neurology, and autoimmunity.
By Application
Key application areas include immunology, neurology, hematology, critical care, and others. In 2024, the immunology & neurology segment held dominance, reflecting rising prevalence of immunological and neurological disorders and expanding therapeutic pipelines. Hematology (e.g., hemophilia care) is also a strong contributor.
By End-User
End-users are hospitals & clinics, clinical research laboratories, and other entities (academic research, specialty centers). Hospitals & clinics hold the highest revenue share, driven by direct administration of plasma-derived therapies to patients. Clinical research labs grow steadily as R&D in novel plasma proteins continues.
Explore the full research report with detailed insights and TOC:https://www.fortunebusinessinsights.com/industry-reports/plasma-fractionation-market-101614
Market Regional Insights
The geographic regions analyzed include North America, Europe, Asia Pacific
North America
In 2024, North America held around USD 20.96 billion in plasma fractionation revenue and dominated the global market. The U.S. remains the largest contributor, powered by advanced healthcare infrastructure, high donation rates, and strong innovation pipelines. For example, Takeda’s BioLife Plasma Services opened its 200th donation center in the U.S. in March 2023, further expanding the plasma supply network.
Europe
Europe ranks second in market share. By 2025, the European market is projected to reach USD 8.50 billion. Countries such as Germany, France, UK, and Italy drive growth, supported by rising awareness of immune and bleeding disorders, and strategic acquisitions (e.g., Kedrion’s moves in Czech plasma collection) to boost capacity and local supply.
Asia Pacific
Asia Pacific is emerging as a growth frontier. By 2025, the region is forecast at USD 7.76 billion. China, India, Japan, and other nations are enhancing healthcare infrastructure, expanding plasma collection, and promoting awareness of plasma therapies. For instance, India is expected to reach about USD 0.94 billion in 2025.
Future Market Scope & Outlook
The global plasma fractionation market’s future hinges on several key trends and evolving dynamics:
Deepening immunoglobulin demand: As more indications emerge (e.g. neurology, autoimmunity, rare diseases), immunoglobulin consumption is set to widen.
Technology shift and hybrid fractionation: Chromatography and hybrid methods will increasingly supplement or replace traditional cold-ethanol approaches to achieve better purity, selectivity and yield.
Regional self-sufficiency and local capacity build-out: Regions like Asia Pacific and Europe will invest more heavily in local plasma collection and processing to reduce import dependence.
About Us:Fortune Business Insights provides expert corporate analysis and accurate data, enabling businesses of all sizes to make timely decisions. We offer customized solutions tailored to each client’s needs, helping them address unique challenges. Our goal is to empower clients with holistic market intelligence and offer granular insights into the market they operate in.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free),
APAC: +91 744 740 1245
Comments